But later the FDA allowed the studies to be conducted under partial clinical hold with low oral dosage. We note that Repros' shares have outperformed the Zacks classified Medical - Biomedical and Genetics industry in the last one year. Repros shares returned 37.1% against a decline of 10.6% for the industry. In a separate press release, the company announced that Larry Dillaha will become its permanent President and CEO effective Apr 10. She was working on an interim basis at the same position since Feb 1.